Recent Updates
Recently added Catalysts
CGON Positive Sentiment

CURE

Monday, March 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology's Cretostimogene has demonstrated a durable response in patients with BCG-unresponsive bladder cancer. The company recently reported positive results from the CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy. Additionally, CG Oncology is actively participating in upcoming investor conferences and research fellowship awards.
Price reaction · baseline $27.05 (2025-03-21 close) · hit pre-market · 2 other CGON headline(s) in the window, move may be shared
day 0 close · peak
+5.5%
day 1
+1.8%
day 3
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Cretostimogene shows a durable response in bladder cancer treatment.
  • Positive initial results from the CORE-1008 trial.
  • CG Oncology's involvement in significant research awards.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Mar 24, 2025 | in-the-news
Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is Cretostimogene used for?

Cretostimogene is used to treat BCG-unresponsive bladder cancer.

What were the results of the CORE-1008 trial?

The CORE-1008 trial reported positive initial results for an intravesical combination therapy.

What is the significance of the recent awards?

CG Oncology announced award recipients for the Non-Muscle Invasive Bladder Cancer Research Fellowship.

When will CG Oncology present at investor conferences?

CG Oncology is scheduled to present at upcoming investor conferences in June.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare Cretostimogene bladder cancer CG Oncology CORE-1008 BCG-unresponsive
Last updated: Mar 24, 2025

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →